Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritisPhilip J. Mease, Subhashis Banerjee, Atul Deodhar et al.|Annals of the Rheumatic Diseases|2022Cited by 212
POS0198 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALPhilip J. Mease, Susana Banerjee, Miroslawa Nowak et al.|Annals of the Rheumatic Diseases|2021Cited by 15
POS1048 SAFETY AND EFFICACY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS: 52-WEEK RESULTS FROM A RANDOMISED PHASE 2 TRIALP. J. Mease, Sibabrata Banerjee, M. Nys et al.|Annals of the Rheumatic Diseases|2022Cited by 5